Cancer feature: cnaPANCAN29

ADK AGAP5 ANAPC16 ANXA11 ANXA7 AP3M1 ASCC1 C10orf105 C10orf11 C10orf54 C10orf55 CAMK2G CDH23 CHCHD1 CHST3 COMTD1 DDIT4 DLG5 DNAJB12 DNAJC9 DUPD1 DUSP13 DYDC1 DYDC2 ECD EIF5AL1 FAM149B1 FAM213A FUT11 KAT6B KCNMA1 MAT1A MCU MICU1 MRPS16 MSS51 MYOZ1 NDST2 NUDT13 NUTM2B NUTM2E OIT3 P4HA1 PLA2G12B PLAC9 PLAU POLR3A PPIF PPP3CB PSAP RP11-574K11.31 RPS24 SAMD8 SEC24C SFTPA1 SFTPA2 SFTPD SH2D4B SPOCK2 SYNPO2L TMEM254 TSPAN14 TTC18 USP54 VCL VDAC2 ZCCHC24 ZMIZ1 ZNF503 ZSWIM8

Known Driver Genes: None

Copy number alternation: gain

Methotrexate

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer